The University of Chicago Comprehensive Cancer Center (UCCCC) is led by a Strong Leadership Team, which effectively represents all components of the academic units Involved In cancer research and clinical care, and tightly links the basic, clinical, translational and population research programs. The Senior Leaders includes 2 Co-Deputy Directors and 7 Associate Directors. Over the past 5 years, strategic changes In the leadership have facilitated the development of an Integrated and shared vision for the cancer programs. New appointments, together with considerable continuity of leadership, have enhanced organizational and planning capabilities. Richard Schilsky, MD (Chief, Section of Hematology/ Oncology) replaced Dr. Vokes (who was appointed Chair of Medicine) as Co-Deputy Director for Clinical Sciences. He works closely with Marsha Rosner, PhD (Chair, Ben May Department for Cancer Research) who remains as the Co-Deputy Director for Basic Sciences. The Associate Directors for Basic Sciences (Geoffrey Greene, PhD, Vice Chair of the Ben May Department for Cancer Research), Clinical Sciences (Mark Ratain, MD, Professor of Medicine, Director, Center for Personalized Therapeutics), and Population Research (Habibul Ahsan, MBBS, MMedSc, Professor of Health Studies, Director, Center for Cancer EpWemiology and Prevention), all recognized as leaders in their fields, continue in their roles. Marcy List, PhD, continues in her role as Associate Director for Administration. James Schilling, PhD, an experienced investigator with expertise in proteomics, now serves as the Associate Director for Core Facilities, and Executive Director of the BSD Office of Shared Research Facilities. In 2011, the UCCCC created two new positions, the Associate Director for Translational Sciences (Ravi Salgia, MD, PhD, Professor of Medicine, Vice Chair for Translational Research, Dept. of Medicine) and the Associate Director for Education (Ezra Cohen, MD, Associate Professor of Medicine, Director of the Hematology/Oncology Fellowship Program). The above individuals are members (with the exception of the Associate Director for Core Facilities) of the UCCCC Executive Committee (EC) and the Cancer Advisory Committee (CAC). The CAC also includes additional leaders of academic units engaged In cancer research and care of patients with cancer, e.g.. Radiation Oncology, Surgical Oncology, Urology and Pediatric Hematology/Oncology. The Deputy Directors and Associate Directors, work closely with the Director, and are responsible for strategic planning, general administration of the UCCCC and Implementation of specific programs within their areas. Together they are responsible for identifying and implementing interdisciplinary efforts, identifying recruitment needs, leading recruitment searches, prioritizing allocation of UCCCC resources (including final decisions about the Pilot Project awards), developing new shared resources, and worthing with the Program Leaders In advancing programmatic goals. Over the past year, this group has taken primary responsibility for developing the UCCCC Strategic Plan.
Advancing the UCCCC's mission, to elucidate the determinants of cancer, to develop cures for cancer, and to prevent cancer, requires a strategic vision and an emphasis on translational and interdisciplinary research The Senior Leadership Team is responsible for developing this vision, and creating the environment and Infrastructure necessary for collaboration among a diverse and dedicated team of outstanding basic, clinical, translational, and population researchers, and trainees.
|Sharifi, Marina N; Mowers, Erin E; Drake, Lauren E et al. (2016) Autophagy Promotes Focal Adhesion Disassembly and Cell Motility of Metastatic Tumor Cells through the Direct Interaction of Paxillin with LC3. Cell Rep 15:1660-72|
|Drazer, Michael W; Stadler, Walter M (2016) The Role of Testosterone in the Treatment of Castration-Resistant Prostate Cancer. Cancer J 22:330-333|
|Epel, Boris; Redler, Gage; Pelizzari, Charles et al. (2016) Approaching Oxygen-Guided Intensity-Modulated Radiation Therapy. Adv Exp Med Biol 876:185-93|
|Sweis, Randy F; Medved, Milica; Towey, Shannon et al. (2016) Dynamic Contrast-Enhanced Magnetic Resonance Imaging as a Pharmacodynamic Biomarker for Pazopanib in Metastatic Renal Carcinoma. Clin Genitourin Cancer :|
|Volden, Paul A; Skor, Maxwell N; Johnson, Marianna B et al. (2016) Mammary Adipose Tissue-Derived Lysophospholipids Promote Estrogen Receptor-Negative Mammary Epithelial Cell Proliferation. Cancer Prev Res (Phila) 9:367-78|
|Stein, Michelle M; Hrusch, Cara L; Gozdz, Justyna et al. (2016) Innate Immunity and Asthma Risk in Amish and Hutterite Farm Children. N Engl J Med 375:411-21|
|Baron, Beverly W; Baron, Rebecca M; Baron, Joseph M (2016) The Relationship between RUVBL1 (Pontin, TIP49, NMP238) and BCL6 in Benign and Malignant Human Lymphoid Tissues. Biochem Biophys Rep 6:1-8|
|King, Andrea C; Hasin, Deborah; O'Connor, Sean J et al. (2016) A Prospective 5-Year Re-examination of Alcohol Response in Heavy Drinkers Progressing in Alcohol Use Disorder. Biol Psychiatry 79:489-98|
|Appelbe, Oliver K; Zhang, Qingbei; Pelizzari, Charles A et al. (2016) Image-Guided Radiotherapy Targets Macromolecules through Altering the Tumor Microenvironment. Mol Pharm 13:3457-3467|
|Morrison, Gladys; Lenkala, Divya; LaCroix, Bonnie et al. (2016) Utility of patient-derived lymphoblastoid cell lines as an ex vivo capecitabine sensitivity prediction model for breast cancer patients. Oncotarget 7:38359-38366|
Showing the most recent 10 out of 534 publications